HUNTER researchers have exposed the double-life of a protein known as RIP1, which they hope will lead to the development of a new generation of targeted melanoma drugs.
The molecule, Receptor-Interacting Protein kinase 1, has previously been linked to naturally occurring cell death but little attention has been paid to its pro-survival function in melanoma cells.
Researchers with the University of Arizona College of Pharmacy and the Arizona Cancer Center have found a novel compound that could be used to target malignant melanoma cells, which are cells that believed to be the cause of many skin cancer-related deaths.
In a new study entitled “Atg7 Overcomes Senescence and Promotes Growth of BrafV600E-Driven Melanoma” researchers at the Rutgers Cancer Institute, New Jersey show the potential added benefit of combining anti-autophagy drugs with BRAF inhibitors to treat melanoma. The study was published in the current online edition of Cancer Discovery.
Pharmacyclics, Inc., a biopharmaceutical company focused on the development and commercialization of innovative small-molecule drugs to treat cancer and immune mediated diseases recently announced that they will present the results for ibrutinib (IMBRUVICA) during the 2015 Annual Meeting of the American Association for Cancer Research (AACR), taking place in Philadelphia between the 18th and the 22nd of April.
